10 May 2012

Use of Gene Modified Blood Stem Cells Counteracts Toxic Effects of Chemotherapy

Blood stem cells can be found in the bone marrow, the soft, spongy interior of bones. Blood stem cells are also called hematopoietic stem cells and are responsible for resupplying blood cells. The blood cells are the red blood cells called the erythrocytes, the platelets which help in blood-clotting, and the leukocytes which are the white blood cells of the immune system.

The process where the body replaces these blood cells is called hematopoiesis. The stem cells in the bone marrow matures and starts to transform to either of the three types of blood cells. This process goes on constantly in the human body. The body also reacts to certain conditions and starts producing more of the blood cells such as movement to a high altitude and serious bleeding. These types of conditions require more blood into the blood stream to compensate for the changes encountered by the human body.

Gene-modified stem cell transplant protects patients from toxic side effects of chemotherapy

For the first time, scientists at Fred Hutchinson Cancer Research Center have transplanted brain cancer patients' own gene-modified blood stem cells in order to protect their bone marrow against the toxic side effects of chemotherapy. Initial results of the ongoing, small clinical trial of three patients with glioblastoma showed that two patients survived longer than predicted if they had not been given the transplants, and a third patient remains alive with no disease progression almost three years after treatment.

"We found that patients were able to tolerate the chemotherapy better and without negative side effects after transplantation of the gene-modified stem cells than patients in previous studies who received the same type of chemotherapy without a transplant of gene-modified stem cells," said Hans-Peter Kiem, M.D., senior and corresponding author of the study published in the May 9 issue of Science Translational Medicine.

Video: Stem Cells From Blood Cells

Kiem, a member of the Clinical Research Division at the Hutchinson Center, said that a major barrier to effective use of chemotherapy to treat cancers like glioblastoma has been the toxicity of chemotherapy drugs to other organs, primarily bone marrow. This results in decreased blood cell counts, increased susceptibility to infections and other side effects. Discontinuing or delaying treatment or reducing the chemotherapy dose is generally required, but that often results in less effective treatment.

In the current study, Kiem and colleagues focused on patients with glioblastoma, an invariably fatal cancer. Many of these patients have a gene called MGMT (O6-methylguanine-DNA-methyltransferase) that is turned on because the promoter for this gene is unmethylated. MGMT is a DNA repair enzyme that counteracts the toxic effect of some chemotherapy agents like temozolomide. Patients with such an unmethylated promoter status have a particularly poor prognosis.

A drug called benzylguanine can block the MGMT gene and make tumor cells sensitive to chemotherapy again, but when given with chemotherapy, the toxic effects of this combination are too much for bone marrow cells, which results in marrow suppression.

By giving bone marrow stem cells P140K, which is a modified version of MGMT, those cells are protected from the toxic effects of benzylguanine and chemotherapy, while the tumor cells are still sensitive to chemotherapy. "P140K can repair the damage caused by chemotherapy and is impervious to the effects of benzylguanine," Kiem said.

"This therapy is analogous to firing at both tumor cells and bone marrow cells, but giving the bone marrow cells protective shields while the tumor cells are unshielded," said Jennifer Adair, Ph.D., who shares first authorship of the study with Brian Beard, Ph.D., both members of Kiem's lab.

The three patients in this study survived an average of 22 months after receiving transplants of their own circulating blood stem cells. One, an Alaskan man, remains alive 34 months after treatment. Median survival for patients with this type of high-risk glioblastoma without a transplant is just over a year.

"Glioblastoma remains one of the most devastating cancers with a median survival of only 12 to 15 months for patients with unmethylated MGMT," said Maciej Mrugala, M.D., the lead neuro oncologist for this study.

As many as 50 percent to 60 percent of glioblastoma patients harbor such chemotherapy-resistant tumors, which makes gene-modified stem cell transplant therapy applicable to a large number of these patients. In addition, there are also other brain tumors such as neuroblastoma or other solid tumors with MGMT-mediated chemo resistance that might benefit from this approach.

The researchers also found that chemotherapy increased the number of gene-modified blood and bone marrow cells in these patients. Kiem said this finding will have implications for other stem cell gene therapy applications where defective bone marrow stem cells can be corrected by gene therapy but their numbers need to be increased to produce a therapeutic benefit, or for patients with HIV/AIDS to increase the number of HIV-resistant stem and T cells.

The clinical trial is open and is recruiting more patients. For more information go to: http://clinicaltrials.gov/ct2/show/NCT00669669.

Researchers from Washington State University, the University of Washington, Dana Farber/Children's Hospital Cancer Center and the Harvard Medical School contributed to the study. The research was funded by grants from the National Institutes of Health and the Heath Foundation.


Fred Hutchinson Cancer Research Center
Science Translational Medicine
Washington State University
University of Washington
Dana Farber/Children's Hospital Cancer Center
Harvard Medical School
National Institutes of Health
Cholesterol Drug Helps Chemotherapy Research in Effectively Treating Cancer
New Development In Chemotherapy Reduces Side Effects
Brain Cancer Vaccine, Heat Shock Protein Peptide Complex 96 (HSPPC-96) , Against Glioblastoma Multiforme Proves Effective
New Developments On Glioblastoma: Cheaper Medication and Clues On Movement and Mechanism of Brain Cancer Cells
New Stem Cell Line Offers Safe and Prolific Source for Disease and Transplant Studies
Newly Discovered Cardiac Stem Cells Repair Damaged Heart
New Organ Transplant Method Without Requiring Anti-Rejection Medicine
Cancer Vaccine Based on Cancer Stem Cell Being Developed
Stem Cells Engineered To Attack HIV Virus